Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 981-987

  Oudard, Stéphane ^a   Elaidi, Reza Thierry ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anticancer therapy; Kidney cancer; Mechanism of action; Metastatic disease; Resistance; Sequential therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; DOVITINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANEMIA; APPETITE; ASTHENIA; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; REVIEW; SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84862827939     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.12.009     Document Type: Review

References (60)

1. Coppin C. Immunotherapy for renal cell cancer in the era of targeted therapy. Exp Rev Anticancer Ther 2008, 8:907-919.
2. Richards F.M., Webster A.R., McMahon R., et al. Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med 1998, 243:527-533.
3. Nickerson M.L., Jaeger E., Shi Y., et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008, 14:4726-4734.
4. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
5. Coppin C., Kollmannsberger C., Le L., Porzsolt F., Wilt T.J. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011, 108:1556-1563.
6. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer, V.2.2011. National Comprehensive Cancer Network Web site. Available at: <>; 2011 [accessed July 6, 2011]. http://www.nccn.org.
8. Escudier B., Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v137-v139.
9. de Reijke T.M., Bellmunt J., van Poppel H., Marreaud S., Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773.
10. Ljungberg B., Cowan N.C., Hanbury D.C., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
11. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
12. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
13. Escudier B., Bellmunt J., Negrier S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
14. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289.
15. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
16. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
17. Huang D., Ding Y., Zhou M., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
18. Rini B.I. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010, 16:1348-1354.
19. Zhang L., Bhasin M., Schor-Bardach R., et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One 2011, 6:e19144.
20. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
21. Serova M, Riveiro M, Dokmak S, Raymond E. Everolimus (RAD001) activity in renal and hepatocellular carcinoma cells resistant to sunitinib and sorafenib. AACR Meeting Abstracts. 2011; abstract 488.
22. Hammers H.J., Verheul H.M., Salumbides B., et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010, 9:1525-1535.
23. Chikazawa M., Inoue K., Fukata S., Karashima T., Shuin T. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology 2008, 75:335-345.
24. Bellmunt J., Gonzales-Larriba J.L., Prior C., et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011, 22:2646-2653.
25. Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
26. Zimmermann K., Schmittel A., Steiner U., et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009, 76:350-354.
27. Eichelberg C., Heuer R., Chun F.K., et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008, 54:1373-1378.
28. Sepulveda J, Maroto P, Andres R, et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. J Clin Oncol 2008; 26(May 20 suppl): Abstract 16100.
29. Porta C., Procopio G., Carteni G., et al. Sequential use of sorafenib and sunitinib in advanced renalcell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011, 108(8 Pt 2):E250-E257.
30. Choueri TK, Brick AJ, McDermott D, et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann Oncol 2008; 19(suppl 8):viii191-192.
31. Dudek A.Z., Zolnierek J., Dham A., Lindgren B.R., Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115:61-67.
32. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34.
33. Procopio G., Verzoni E., Iacovelli R., et al. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther 2011, 11:1631-1640.
34. Richter S., Pfister D., Thuer D., Engelmann U.H., Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 2008, 31(Suppl.):234-236.
35. Vickers M.M., Choueiri T.K., Rogers M., et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010, 76:430-434.
36. Mancuso AP, Donato De Paola E, Catalano A, et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFRTKI antiangiogenic treatment. J Clin Oncol 2009; 27(Suppl): Abstract e16027.
37. Garcia J.A., Hutson T.E., Elson P., et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010, 116:5383-5390.
38. Di Lorenzo G., Carteni G., Autorino R., et al. Phase II study of sorafenib in patients with sunitinibrefractory metastatic renal cell cancer. J Clin Oncol 2009, 27:4469-4474.
39. Jac J, Amato RJ, Geissinger S, Saxena S, Willis JP. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J Clin Oncol 2008; 18(suppl):Abstract 5113.
40. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
41. Rini BI, Escudier B, Tomkzac P, et al. Comparative eff ectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; doi: doi:10.1016/S0140-6736(11)61613-9.
42. Launay-Vacher V., Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009, 20:81-82.
43. Patel P., Srinivas S. Toxicities of targeted agents in advanced renal cell carcinoma. Curr Clin Pharmacol 2011, 6:181-188.
44. Calvo E, Escudier B, Motzer RJ, et al.: Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 versus 2 previous vascular endothelial growth factor receptortyrosine kinase inhibitor therapies enrolled in the phase 3 RECORD-1 study. Eur J Cancer 2011, in press.
45. Di Lorenzo G., Casciano R., Malangone E., et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Exp Opin Pharmacother 2011, 12:1491-1497.
46. Albiges L, Lacovelli R, Porta C, Houede N, Laguerre B, Procopio G et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib in metastatic renal cell carcinoma: Is there any active treatment? Eur J Cancer 2011; 47(suppl 1):Abstract 7143.
47. Heng D.Y., Mackenzie M.J., Vaishampayan U.N., et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy. J Clin Oncol 2011, 29(7 suppl):305.
48. Busch J., Seidel C., Weikert S., et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer 2011, 11:295.
49. Di Lorenzo G., Buonerba C., Federico P., et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010, 58:906-911.
50. Blesius A, Beuselinck B, Chevreau C, et al. Are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD 1 trial. 2010; 21(suppl 8):viii271-303.
51. Gruenwald V, Seidel C, Fenner M, Heuser M, Ganser A. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Presented at ASCO Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, California; Abstract.
52. Grunwald V., Weikert S., Seidel C., et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie 2011, 34:310-314.
53. Angevin E, Grunwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 2011; 29(suppl):Abstract 4551.
54. Porta C, Paglino C, Procopio G, et al. Optimizing the sequential treatment of metastatic renal cell carcinoma (MRCC) - a retrospective, multicener, analysis of 40 patients treated with either sorafenib, an mTOR inhibitor (mTORI) and sunitinib, or sunitinib, an mTORI and sorafenib. Eur J Cancer 2011; 47(suppl 1):Abstract 7131.
55. Grunwald V., Seidel C., Fenner M., et al. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer 2011, 105(11):1635-1639.
56. Lopes de Menezes D.E., Peng J., Garrett E.N., et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005, 11:5281-5291.
57. Trudel S., Li Z.H., Wei E., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005, 105:2941-2948.
58. Shi M, Kim KB, Chesney J, et al. Effect of TKI258 on plasma biomarkers and pharmcokinetics inpatients with advanced melanoma. J Clin Oncol 2009; 27(15 suppl):Abstract 9020.
59. Oudard S. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res 2010, 30:5223-5225.
60. Gerlinger M, Albiges L. The personalized RNA interference to enhance the delivery of individualized cytotoxic and targeted therapeutics (PREDICT) approach to biomarker discovery in renal cell carcinoma. J Clin Oncol 2011; 29(suppl):Abstract TPS179.